Navigation Links
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
Date:4/8/2009

AMSTERDAM, April 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations. Data was presented by the company's principal investigator Dr. Denis Claude Roy during the prestigious Presidential Symposium at the Annual European Bone Marrow Transplantation meeting (EBMT) in Goteborg, Sweden, on Monday, March 30, 2009. Only the 6 highest ranked presentations, representing the most promising new developments in the transplantation field, were selected for this Symposium.

ATIR(TM), a donor lymphocyte cell based preparation depleted of allo-reactive T-cells, is under development to prevent acute Graft versus Host Disease (GvHD) and allow for early immune reconstitution following a bone marrow transplantation with a fully mismatched (haplo-identical) donor.

Dr. Roy's presentation of clinical results from 19 end stage blood cancer patients with high risk leukemia and/or lymphoma using ATIR(TM) was very well received. These patients, each of whom did not have a matched donor available, were treated in a phase I/II dose escalating study with ATIR(TM) in a mismatched transplantation setting. No immune suppressants were used, which is in contrast to conventional transplant procedures. Nevertheless, no cases of severe grade III/IV acute GvHD occurred after ATIR(TM) infusion. Furthermore, the clinical data showed a reduction in the frequency of infectious episodes in the cohorts treated with the higher doses of ATIR(TM), as compared to the low dose cohorts. To date, patients in the higher dose cohorts show high survival rates (75%) with no transplant related mortality (TRM).

These results show that the selective depletion of allo-reactive T-cells in the ATIR(TM) cell based product by the proprietary photo-sensitizing agent TH9402 is highly effective and can result in fast and adequate immune reco
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
2. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
5. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
6. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
7. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
8. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
9. New Pharmaxis Board Appointment
10. Pharmaxis Investor Conference Call
11. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... (PRWEB) December 22, 2014 ITRA Global, ... and occupiers of commercial real estate, has further expanded ... offices in Perth and Brisbane, Western Australia, reports Mylinda ... directors. , ITRA Global / ACORPP (Australian Corporate ... independent consultancy company providing property services to a wide ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... FL (PRWEB) December 18, 2014 ... the nation’s leading specialty pharmacies, has an expanded ... as clinical pharmacy consultants for prescriber offices in ... expertise. , “We have a variety of ... For example, those specializing in hepatitis C help ...
(Date:12/19/2014)... Boston, MA (PRWEB) December 18, 2014 ... software, announced the appointment of Siri Bryant as the ... the new Director of Core Implementations. These two new ... provide outstanding customer service by ensuring that iLab continues ... , “In the last four years, iLab has been ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... 4 Pfizer,s loss of some top,talent, including ... of two,Michigan companies teaming to help speed research ... bone disease, rheumatoid arthritis and,osteoporosis., Velcura Therapeutics ... biotechnology company will work with Dr. Sliskovic and ...
... Support For Cutting-Edge Health Research Will Create Jobs, Attract ... ... /PRNewswire/ - The Ontario government is providing $150,million through the Next ... Minister of Research and,Innovation John Wilkinson has announced., "Attracting these ...
... of Cancer and Women,s Health to Assist Company in ... ... Needs, REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, February ... its Medical Advisory Board. Rosetta Genomics has,assembled world-leading clinicians in ...
Cached Biology Technology:Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2Sparking Growth In Ontario's Biopharmaceutical Industry 2Sparking Growth In Ontario's Biopharmaceutical Industry 3Rosetta Genomics Establishes Medical Advisory Board 2Rosetta Genomics Establishes Medical Advisory Board 3Rosetta Genomics Establishes Medical Advisory Board 4Rosetta Genomics Establishes Medical Advisory Board 5
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... can transmit Lyme disease from host animals to humans, ... when spending time outdoors. University of Illinois ... black-legged ticks (also known as deer ticks), their host ... and Piatt Counties. The survey confirmed the presence ...
... RIVERSIDE, Calif. ( www.ucr.edu ) -- A year ago, ... engineering at the UC Riverside Bourns College of Engineering, ... to study water quality and sustainability issues in a ... a a deep familiarity with Skype, a baby daughter ...
... N.C. -- As physician-guided robots routinely operate on patients ... eliminate a surprising element from that scenario -- the ... have demonstrated that a robot -- without any human ... in simulated human organs, guide a device to the ...
Cached Biology News:Research results confirm need for protection against ticks that carry Lyme disease 2Research results confirm need for protection against ticks that carry Lyme disease 3A baby, Skype and water research partnership with Israel 2A baby, Skype and water research partnership with Israel 3Next generation surgical robots: Where's the doctor? 2Next generation surgical robots: Where's the doctor? 3